Ten Years After the ADA Amendment Act (2008): The Relationship Between ADA Employment Discrimination and Substance Use Disorders.


Journal

Psychiatric services (Washington, D.C.)
ISSN: 1557-9700
Titre abrégé: Psychiatr Serv
Pays: United States
ID NLM: 9502838

Informations de publication

Date de publication:
01 07 2019
Historique:
pubmed: 18 4 2019
medline: 7 5 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

Title I of the Americans with Disabilities Act (ADA) provides protection against discrimination on the basis of disability. This article explores how the courts have dealt with provisions limiting these protections for persons with substance use disorders. Specifically, the ADA allows employees with substance use disorders to be held to the same standards as other employees, suggesting that employers may not be required to provide reasonable accommodations. Moreover, employees "currently engaging in the illegal use of drugs" are excluded from ADA coverage. This article reviewed all published federal appellate court opinions involving cases in which a substance use disorder was the basis for a claim of employment-related discrimination in violation of the ADA. In 26 cases identified, the lower courts ruled in favor of the employer 25 times, and the appellate courts reversed four of these rulings. The cases highlight three important limitations of ADA protections for persons with substance use disorders: the dilemma of needing to prove that one's substance use disorder limits major life activities while simultaneously arguing that one is qualified for the job; expansive interpretations of "current" drug use and the period of sobriety needed to qualify for ADA protections; and restrictions on the extent to which a qualifying disability can serve as a legal excuse for substance use-related misconduct. The protections afforded by the ADA for individuals with substance use disorders are restricted by what appears to be the statute's moralizing on drug and alcohol use and those who use these substances.

Identifiants

pubmed: 30991909
doi: 10.1176/appi.ps.201800574
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

596-603

Auteurs

Elie G Aoun (EG)

Division of Law, Ethics, and Psychiatry (Aoun and Appelbaum) and Center for Research on Ethical, Legal, and Social Implications of Psychiatric, Neurologic, and Behavioral Genetics (Appelbaum), Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York.

Paul S Appelbaum (PS)

Division of Law, Ethics, and Psychiatry (Aoun and Appelbaum) and Center for Research on Ethical, Legal, and Social Implications of Psychiatric, Neurologic, and Behavioral Genetics (Appelbaum), Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH